ClinicalTrials.gov ID NCT02665065
Sponsor Actinium Pharmaceuticals
Local PI Arjun Datt Law
Conditions
- Acute Myeloid Leukemia
- Leukemia, Acute Myeloid
- Myeloid Leukemia, Acute
- Leukemia, Myeloid, Acute
SIERRA is a pivotal Phase 3 randomized controlled study of Iomab-B in Relapsed or Refractory AML patients. The SIERRA trial has a primary endpoint of durable Complete Remission (dCR) at six months and a secondary endpoint of overall survival following randomization to Iomab-B, as well as Event-Free Survival. Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, in a potentially safer and more efficacious manner than intensive chemotherapy conditioning that is the current standard of care in bone marrow transplant conditioning.